Site for A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis

Brief description of study

Site for The purpose of this study is to measure clinical efficacy (based on TIS) of oral brepocitinib compared with placebo in participants with dermatomyositis


Clinical Study Identifier: s22-00734
ClinicalTrials.gov Identifier: NCT05437263
Principal Investigator: Alisa N Femia.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.